Kiora Free Cash Flow per Share vs Price to Sales Ratio Analysis

KPRX Stock

USD 0.51 0.04 7.27%

Kiora Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Kiora Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Kiora Pharmaceuticals is a good investment. Please check the relationship between Kiora Pharmaceuticals Free Cash Flow Per Share and its Price To Sales Ratio accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiora Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.

Free Cash Flow Per Share vs Price To Sales Ratio

Free Cash Flow per Share vs Price to Sales Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Kiora Pharmaceuticals Free Cash Flow per Share account and Price to Sales Ratio. At this time, the significance of the direction appears to have strong relationship.

The correlation between Kiora Pharmaceuticals' Free Cash Flow per Share and Price to Sales Ratio is 0.71. Overlapping area represents the amount of variation of Free Cash Flow per Share that can explain the historical movement of Price to Sales Ratio in the same time period over historical financial statements of Kiora Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Kiora Pharmaceuticals' Free Cash Flow per Share and Price to Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow per Share of Kiora Pharmaceuticals are associated (or correlated) with its Price to Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price to Sales Ratio has no effect on the direction of Free Cash Flow per Share i.e., Kiora Pharmaceuticals' Free Cash Flow per Share and Price to Sales Ratio go up and down completely randomly.

Correlation Coefficient

0.71

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Free Cash Flow Per Share

The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Kiora Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Kiora Pharmaceuticals sales, a figure that is much harder to manipulate than other Kiora Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period.

Most indicators from Kiora Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kiora Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiora Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.At this time, Kiora Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 94.8 K in 2024, whereas Enterprise Value Over EBITDA is likely to drop (0.02) in 2024.

Kiora Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Current Deferred Revenue	Good Will	Intangible Assets	Other Liab
Total Assets		-0.49	0.87	0.23	0.93	0.73	-0.68	-0.82	0.31	0.67	0.88	-0.5	0.67	0.43	0.26	-0.88	0.82	0.95	-0.87	0.76	-0.52	0.49	0.47	-0.73	0.61	0.65
Short Long Term Debt Total	-0.49		-0.54	0.04	-0.55	-0.26	0.69	0.33	-0.03	-0.52	-0.3	0.76	-0.52	-0.23	-0.16	0.51	-0.42	-0.44	0.55	-0.54	1.0	-0.3	-0.29	0.3	-0.13	-0.21
Other Current Liab	0.87	-0.54		0.45	0.82	0.57	-0.62	-0.7	0.62	0.6	0.75	-0.51	0.6	0.42	0.24	-0.84	0.73	0.82	-0.77	0.68	-0.55	0.3	0.62	-0.51	0.54	0.5
Total Current Liabilities	0.23	0.04	0.45		0.18	-0.04	-0.32	-0.01	0.56	0.39	0.08	0.22	0.39	-0.15	-0.13	-0.36	0.42	0.1	-0.14	0.35	0.05	0.34	0.88	0.26	-0.18	-0.24
Total Stockholder Equity	0.93	-0.55	0.82	0.18		0.56	-0.69	-0.79	0.3	0.69	0.77	-0.6	0.69	0.47	0.33	-0.97	0.8	0.92	-0.99	0.76	-0.57	0.51	0.42	-0.69	0.43	0.56
Property Plant And Equipment Net	0.73	-0.26	0.57	-0.04	0.56		-0.5	-0.67	0.11	0.53	0.6	-0.33	0.53	0.46	0.25	-0.45	0.48	0.7	-0.48	0.61	-0.27	0.17	0.15	-0.71	0.66	0.7
Net Debt	-0.68	0.69	-0.62	-0.32	-0.69	-0.5		0.31	-0.15	-0.96	-0.27	0.51	-0.96	-0.14	0.09	0.71	-0.57	-0.53	0.69	-0.95	0.67	-0.61	-0.45	0.31	-0.03	-0.08
Retained Earnings	-0.82	0.33	-0.7	-0.01	-0.79	-0.67	0.31		-0.11	-0.35	-0.82	0.45	-0.35	-0.77	-0.72	0.68	-0.61	-0.89	0.7	-0.48	0.36	-0.26	-0.34	0.91	-0.7	-0.91
Accounts Payable	0.31	-0.03	0.62	0.56	0.3	0.11	-0.15	-0.11		0.15	0.31	0.09	0.15	0.01	-0.15	-0.41	0.32	0.25	-0.29	0.18	-0.03	-0.05	0.37	0.11	0.21	-0.01
Cash	0.67	-0.52	0.6	0.39	0.69	0.53	-0.96	-0.35	0.15		0.24	-0.41	1.0	0.21	-0.02	-0.71	0.56	0.51	-0.67	0.98	-0.5	0.65	0.49	-0.35	0.03	0.12
Non Current Assets Total	0.88	-0.3	0.75	0.08	0.77	0.6	-0.27	-0.82	0.31	0.24		-0.38	0.24	0.36	0.3	-0.7	0.76	0.9	-0.7	0.35	-0.35	0.26	0.32	-0.7	0.75	0.74
Non Currrent Assets Other	-0.5	0.76	-0.51	0.22	-0.6	-0.33	0.51	0.45	0.09	-0.41	-0.38		-0.41	-0.36	-0.27	0.53	-0.38	-0.52	0.62	-0.46	0.77	-0.26	-0.09	0.45	-0.27	-0.38
Cash And Short Term Investments	0.67	-0.52	0.6	0.39	0.69	0.53	-0.96	-0.35	0.15	1.0	0.24	-0.41		0.21	-0.02	-0.71	0.56	0.51	-0.67	0.98	-0.5	0.65	0.49	-0.35	0.03	0.12
Net Receivables	0.43	-0.23	0.42	-0.15	0.47	0.46	-0.14	-0.77	0.01	0.21	0.36	-0.36	0.21		0.89	-0.34	0.03	0.54	-0.41	0.35	-0.23	-0.03	0.09	-0.67	0.61	0.8
Common Stock Shares Outstanding	0.26	-0.16	0.24	-0.13	0.33	0.25	0.09	-0.72	-0.15	-0.02	0.3	-0.27	-0.02	0.89		-0.21	0.04	0.42	-0.26	0.1	-0.17	0.02	0.14	-0.61	0.43	0.74
Non Current Liabilities Total	-0.88	0.51	-0.84	-0.36	-0.97	-0.45	0.71	0.68	-0.41	-0.71	-0.7	0.53	-0.71	-0.34	-0.21		-0.83	-0.86	0.97	-0.77	0.53	-0.55	-0.54	0.55	-0.28	-0.39
Other Current Assets	0.82	-0.42	0.73	0.42	0.8	0.48	-0.57	-0.61	0.32	0.56	0.76	-0.38	0.56	0.03	0.04	-0.83		0.76	-0.76	0.57	-0.45	0.52	0.64	-0.49	0.25	0.35
Other Stockholder Equity	0.95	-0.44	0.82	0.1	0.92	0.7	-0.53	-0.89	0.25	0.51	0.9	-0.52	0.51	0.54	0.42	-0.86	0.76		-0.88	0.63	-0.47	0.39	0.37	-0.82	0.62	0.73
Total Liab	-0.87	0.55	-0.77	-0.14	-0.99	-0.48	0.69	0.7	-0.29	-0.67	-0.7	0.62	-0.67	-0.41	-0.26	0.97	-0.76	-0.88		-0.74	0.57	-0.5	-0.35	0.63	-0.34	-0.47
Total Current Assets	0.76	-0.54	0.68	0.35	0.76	0.61	-0.95	-0.48	0.18	0.98	0.35	-0.46	0.98	0.35	0.1	-0.77	0.57	0.63	-0.74		-0.53	0.61	0.48	-0.46	0.16	0.26
Short Term Debt	-0.52	1.0	-0.55	0.05	-0.57	-0.27	0.67	0.36	-0.03	-0.5	-0.35	0.77	-0.5	-0.23	-0.17	0.53	-0.45	-0.47	0.57	-0.53		-0.29	-0.29	0.31	-0.18	-0.25
Common Stock	0.49	-0.3	0.3	0.34	0.51	0.17	-0.61	-0.26	-0.05	0.65	0.26	-0.26	0.65	-0.03	0.02	-0.55	0.52	0.39	-0.5	0.61	-0.29		0.37	-0.3	-0.2	-0.02
Current Deferred Revenue	0.47	-0.29	0.62	0.88	0.42	0.15	-0.45	-0.34	0.37	0.49	0.32	-0.09	0.49	0.09	0.14	-0.54	0.64	0.37	-0.35	0.48	-0.29	0.37		-0.05	0.02	0.08
Good Will	-0.73	0.3	-0.51	0.26	-0.69	-0.71	0.31	0.91	0.11	-0.35	-0.7	0.45	-0.35	-0.67	-0.61	0.55	-0.49	-0.82	0.63	-0.46	0.31	-0.3	-0.05		-0.59	-0.83
Intangible Assets	0.61	-0.13	0.54	-0.18	0.43	0.66	-0.03	-0.7	0.21	0.03	0.75	-0.27	0.03	0.61	0.43	-0.28	0.25	0.62	-0.34	0.16	-0.18	-0.2	0.02	-0.59		0.88
Other Liab	0.65	-0.21	0.5	-0.24	0.56	0.7	-0.08	-0.91	-0.01	0.12	0.74	-0.38	0.12	0.8	0.74	-0.39	0.35	0.73	-0.47	0.26	-0.25	-0.02	0.08	-0.83	0.88

Click cells to compare fundamentals

Kiora Pharmaceuticals Account Relationship Matchups

Kiora Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	10.1M	15.2M	18.1M	18.7M	13.7M	11.7M
Short Long Term Debt Total	83.9K	362.1K	209.4K	105.8K	106.9K	101.5K
Other Current Liab	1.1M	1.3M	1.3M	2.2M	1.4M	1.3M
Total Current Liabilities	1.4M	1.8M	1.6M	3.3M	1.6M	3.2M
Total Stockholder Equity	6.6M	7.0M	9.2M	11.4M	6.1M	6.4M
Property Plant And Equipment Net	16.8K	30.6K	283.4K	172.2K	115.0K	76.8K
Net Debt	(3.7M)	(823.6K)	(7.6M)	(5.9M)	(2.3M)	(2.5M)
Retained Earnings	(100.2M)	(108.3M)	(124.7M)	(134.5M)	(147.0M)	(154.3M)
Accounts Payable	210.3K	434.8K	160.6K	1.0M	206.3K	195.9K
Cash	3.8M	1.2M	7.9M	6.0M	2.5M	4.7M
Non Current Assets Total	5.8M	13.3M	9.1M	11.0M	9.0M	6.1M
Non Currrent Assets Other	114.4K	102.1K	88.0K	82.3K	40.8K	38.7K
Cash And Short Term Investments	3.8M	1.2M	7.9M	6.0M	2.5M	4.7M
Net Receivables	4.9K	91.0K	529.6K	1.4M	2.0M	2.2M
Common Stock Shares Outstanding	79.5K	114.8K	241.1K	732.3K	4.8M	5.1M
Liabilities And Stockholders Equity	10.1M	15.2M	18.1M	18.7M	13.7M	11.7M
Non Current Liabilities Total	2.1M	6.4M	7.2M	4.0M	6.0M	10.2M
Other Current Assets	542.7K	533.5K	606.5K	343.1K	233.4K	368.7K
Other Stockholder Equity	106.7M	115.3M	133.9M	146.0M	153.2M	93.1M
Total Liab	3.5M	8.2M	8.8M	7.3M	7.6M	12.5M
Total Current Assets	4.3M	1.8M	9.0M	7.7M	4.7M	5.6M
Accumulated Other Comprehensive Income	139.5K	(802.0)	(86.4K)	(182.7K)	(182.8K)	(173.7K)
Short Term Debt	83.9K	48.3K	118.8K	105.8K	47.1K	44.7K
Common Stock	40.8K	55.6K	126.6K	18.0K	77.1K	101.9K
Intangible Assets	4.1M	9.7M	8.7M	10.7M	8.8M	7.9M
Other Liab	1.5M	2.1M	6.1M	7.1M	8.2M	8.6M
Net Tangible Assets	7.2M	4.9M	3.3M	9.1M	10.4M	10.9M
Capital Lease Obligations	83.9K	83.9K	209.4K	105.8K	106.9K	96.0K
Net Invested Capital	6.6M	7.3M	9.2M	11.4M	6.1M	7.5M
Non Current Liabilities Other	1.7M	5.3M	6.5M	3.3M	5.1M	3.8M
Net Working Capital	2.9M	37.8K	7.4M	4.4M	3.1M	2.5M
Property Plant Equipment	43.5K	16.8K	30.6K	283.4K	325.9K	342.2K
Capital Stock	40.8K	55.6K	126.6K	18.0K	77.1K	100.8K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Kiora Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kiora Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kiora Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kiora Pharmaceuticals Stock:

How To Invest In Kiora

Details

Is Kiora Stock a good investment?

Details

What is Kiora Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiora Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.

You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Complementary Tools for Kiora Stock analysis

When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.

Is Kiora Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiora Pharmaceuticals. If investors know Kiora will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiora Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.69)

Revenue Per Share

0.002

Return On Assets

(0.34)

Return On Equity

(1.43)

The market value of Kiora Pharmaceuticals is measured differently than its book value, which is the value of Kiora that is recorded on the company's balance sheet. Investors also form their own opinion of Kiora Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiora Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiora Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiora Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Kiora Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kiora Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiora Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Kiora Free Cash Flow per Share vs Price to Sales Ratio Analysis

Free Cash Flow Per Share vs Price To Sales Ratio

Free Cash Flow per Share vs Price to Sales Ratio Correlation Analysis

Correlation Coefficient

Free Cash Flow Per Share

Price To Sales Ratio

Kiora Pharmaceuticals fundamental ratios Correlations

Kiora Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Kiora Pharmaceuticals fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Kiora Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Short Term Debt	+ 1.0	Short Long Term Debt Total
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 0.98	Cash
Total Current Assets	+ 0.98	Cash And Short Term Investments
Total Liab	+ 0.97	Non Current Liabilities Total
Other Stockholder Equity	+ 0.95	Total Assets

Total Liab	- 0.99	Total Stockholder Equity
Non Current Liabilities Total	- 0.97	Total Stockholder Equity
Cash And Short Term Investments	- 0.96	Net Debt
Cash	- 0.96	Net Debt
Total Current Assets	- 0.95	Net Debt
Other Liab	- 0.91	Retained Earnings